JP2010180210A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010180210A5 JP2010180210A5 JP2010034701A JP2010034701A JP2010180210A5 JP 2010180210 A5 JP2010180210 A5 JP 2010180210A5 JP 2010034701 A JP2010034701 A JP 2010034701A JP 2010034701 A JP2010034701 A JP 2010034701A JP 2010180210 A5 JP2010180210 A5 JP 2010180210A5
- Authority
- JP
- Japan
- Prior art keywords
- antitumor
- drug
- agent
- inhibitor
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002246 antineoplastic agent Substances 0.000 claims 53
- 229940041181 antineoplastic drug Drugs 0.000 claims 33
- 239000000203 mixture Substances 0.000 claims 9
- 239000000126 substance Substances 0.000 claims 7
- 229940034982 antineoplastic agent Drugs 0.000 claims 6
- 229960004562 carboplatin Drugs 0.000 claims 6
- 190000008236 carboplatin Chemical compound 0.000 claims 6
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims 6
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 229960004316 cisplatin Drugs 0.000 claims 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 5
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 230000006907 apoptotic process Effects 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 239000002254 cytotoxic agent Substances 0.000 claims 4
- 231100000599 cytotoxic agent Toxicity 0.000 claims 4
- 239000002502 liposome Substances 0.000 claims 4
- 230000033616 DNA repair Effects 0.000 claims 3
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims 3
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000000411 inducer Substances 0.000 claims 3
- 150000002632 lipids Chemical class 0.000 claims 3
- 230000022983 regulation of cell cycle Effects 0.000 claims 3
- 230000002195 synergetic effect Effects 0.000 claims 3
- 230000020172 G2/M transition checkpoint Effects 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 239000003277 telomerase inhibitor Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 2
- 229960002066 vinorelbine Drugs 0.000 claims 2
- 229940126074 CDK kinase inhibitor Drugs 0.000 claims 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 claims 1
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 claims 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims 1
- 230000008051 G1/S transition checkpoint Effects 0.000 claims 1
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 229940123582 Telomerase inhibitor Drugs 0.000 claims 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 230000000118 anti-neoplastic effect Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical group COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000000099 in vitro assay Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 230000002438 mitochondrial effect Effects 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 231100000337 synergistic cytotoxicity Toxicity 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32667101P | 2001-10-03 | 2001-10-03 | |
| US60/326,671 | 2001-10-03 | ||
| US34152901P | 2001-12-17 | 2001-12-17 | |
| US60/341,529 | 2001-12-17 | ||
| US35675902P | 2002-02-15 | 2002-02-15 | |
| US60/356,759 | 2002-02-15 | ||
| CA2,383,529 | 2002-04-23 | ||
| CA002383259A CA2383259A1 (en) | 2002-04-23 | 2002-04-23 | Synergistic compositions |
| US40198402P | 2002-08-07 | 2002-08-07 | |
| US60/401,984 | 2002-08-07 | ||
| US40873302P | 2002-09-06 | 2002-09-06 | |
| US60/408,733 | 2002-09-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003532029A Division JP4778679B2 (ja) | 2001-10-03 | 2002-10-03 | 併用薬剤を送達するための組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010180210A JP2010180210A (ja) | 2010-08-19 |
| JP2010180210A5 true JP2010180210A5 (enExample) | 2010-12-02 |
| JP4926256B2 JP4926256B2 (ja) | 2012-05-09 |
Family
ID=32475852
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003532029A Expired - Lifetime JP4778679B2 (ja) | 2001-10-03 | 2002-10-03 | 併用薬剤を送達するための組成物 |
| JP2010034701A Expired - Lifetime JP4926256B2 (ja) | 2001-10-03 | 2010-02-19 | 併用薬剤を送達するための組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003532029A Expired - Lifetime JP4778679B2 (ja) | 2001-10-03 | 2002-10-03 | 併用薬剤を送達するための組成物 |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP1432402B1 (enExample) |
| JP (2) | JP4778679B2 (enExample) |
| AT (1) | ATE345775T1 (enExample) |
| AU (1) | AU2002331480B2 (enExample) |
| CA (1) | CA2462369C (enExample) |
| CY (1) | CY1105953T1 (enExample) |
| DE (1) | DE60216305T2 (enExample) |
| DK (1) | DK1432402T3 (enExample) |
| ES (1) | ES2272768T3 (enExample) |
| IL (2) | IL161214A (enExample) |
| PT (1) | PT1432402E (enExample) |
| WO (1) | WO2003028696A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2383259A1 (en) | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| CA2527130A1 (en) * | 2003-04-02 | 2004-10-14 | Paul Tardi | Pharmaceutical compositions containing active agents having a lactone group and transition metal ions |
| EP1608337A2 (en) * | 2003-04-02 | 2005-12-28 | Celator Technologies Inc. | Combination compositions of camptothecins and fluoropyrimidines |
| WO2004087105A1 (en) * | 2003-04-02 | 2004-10-14 | Celator Pharmaceuticals, Inc. | Combination formulations of platinum agents and fluoropyrimidines |
| NZ551748A (en) * | 2004-06-01 | 2010-02-26 | Yakult Honsha Kk | Irinotecan formulation |
| IL180785A (en) | 2004-07-19 | 2014-03-31 | Celator Pharmaceuticals Inc | Preparations containing particulate structures for the release of active substances |
| CA2581133A1 (en) * | 2004-09-20 | 2006-03-30 | British Columbia Cancer Agency | Free or liposomal gemcitabine alone or in combination with free or liposomal idarubicin |
| CN101072588B (zh) | 2004-10-06 | 2012-11-28 | 不列颠哥伦比亚抗癌机构 | 用于治疗癌症的具有改善的药物保留的脂质体 |
| WO2007044748A2 (en) * | 2005-10-11 | 2007-04-19 | University Of Pittsburgh | Sphingomyelin liposomes for the treatment of hyperactive bladder disorders |
| EP1951239A2 (en) * | 2005-10-25 | 2008-08-06 | Celator Pharmaceuticals, Inc. | Fixed ratio drug combination treatments for solid tumors |
| US20090148506A1 (en) * | 2005-12-22 | 2009-06-11 | Awa Dicko | Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof |
| EP2049106A2 (en) * | 2006-07-14 | 2009-04-22 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US20080248097A1 (en) * | 2007-02-26 | 2008-10-09 | Kwon Glen S | Polymeric micelles for combination drug delivery |
| ES2706023T3 (es) * | 2007-08-16 | 2019-03-27 | Biocompatibles Uk Ltd | Administración de combinaciones de fármacos |
| CN101878024B (zh) | 2007-11-28 | 2014-04-09 | 塞拉特药物股份有限公司 | 改良的紫杉烷递送系统 |
| CL2009000647A1 (es) * | 2008-04-04 | 2010-06-04 | Chugai Pharmaceutical Co Ltd | Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto. |
| WO2010043050A1 (en) | 2008-10-16 | 2010-04-22 | Celator Pharmaceuticals Corporation | Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| WO2016141167A1 (en) | 2015-03-03 | 2016-09-09 | Cureport, Inc. | Combination liposomal pharmaceutical formulations |
| EP3267975A4 (en) | 2015-03-09 | 2018-08-08 | The Regents of the University of California | Polymer-drug conjugates for combination anticancer therapy |
| SG10201912394VA (en) | 2015-07-15 | 2020-02-27 | Celator Pharmaceuticals Inc | Improved nanoparticle delivery systems |
| CN105434437B (zh) * | 2015-12-01 | 2018-03-02 | 山东大学 | 一种奥沙利铂和伊立替康类药物共载脂质体及其制备方法 |
| CN106619509B (zh) * | 2016-12-21 | 2020-02-18 | 山东大学 | 一种奥沙利铂和伊立替康共载载药脂肪乳及其制备方法 |
| US20230093147A1 (en) * | 2020-03-09 | 2023-03-23 | President And Fellows Of Harvard College | Methods and compositions relating to improved combination therapies |
| US11980636B2 (en) | 2020-11-18 | 2024-05-14 | Jazz Pharmaceuticals Ireland Limited | Treatment of hematological disorders |
| EP4267136A4 (en) * | 2020-12-23 | 2025-02-05 | Cascade Prodrug Inc. | Combination therapy with a vinca alkaloid n-oxide and an immune checkpoint inhibitor |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL26210A (en) * | 1965-08-02 | 1970-12-24 | Merck & Co Inc | Pharmaceutical compositions containing substituted sulphoxides |
| JP3213471B2 (ja) * | 1994-04-13 | 2001-10-02 | ポーラ化成工業株式会社 | 薬効成分含有リポソーム製剤の製造方法 |
| JP5124066B2 (ja) * | 1999-03-24 | 2013-01-23 | イギリス国 | ポリカチオン性炭水化物のワクチンにおける免疫賦活剤としての使用 |
| JP2003524624A (ja) * | 1999-04-09 | 2003-08-19 | ジェシー エル エス オウ | 治療薬の組織への送達を高める方法及び組成物 |
| CA2377385A1 (en) * | 1999-06-03 | 2000-12-14 | Jessie L.S. Au | Methods and compositions for modulating cell proliferation and cell death |
| US6352996B1 (en) * | 1999-08-03 | 2002-03-05 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| PL203128B1 (pl) * | 1999-09-09 | 2009-08-31 | Univ California | Liposom zawierający taksan i zastosowanie liposomu kationowego |
| CA2387145A1 (en) * | 1999-10-14 | 2001-04-19 | Valerio Ditizio | Liposome encapsulated silver salt compositions |
| US6511676B1 (en) * | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| EP1484332A3 (en) * | 2000-02-10 | 2009-01-21 | Liplasome Pharma A/S | Lipid-based drug delivery system for administration of a drug substance |
| JP2003527441A (ja) * | 2000-03-22 | 2003-09-16 | グラクソ グループ リミテッド | 細胞周期を阻止する薬剤及び抗体を含む医薬 |
-
2002
- 2002-10-03 PT PT02766997T patent/PT1432402E/pt unknown
- 2002-10-03 JP JP2003532029A patent/JP4778679B2/ja not_active Expired - Lifetime
- 2002-10-03 CA CA002462369A patent/CA2462369C/en not_active Expired - Lifetime
- 2002-10-03 EP EP02766997A patent/EP1432402B1/en not_active Expired - Lifetime
- 2002-10-03 WO PCT/CA2002/001500 patent/WO2003028696A2/en not_active Ceased
- 2002-10-03 ES ES02766997T patent/ES2272768T3/es not_active Expired - Lifetime
- 2002-10-03 DK DK02766997T patent/DK1432402T3/da active
- 2002-10-03 EP EP06009230A patent/EP1693052A1/en not_active Withdrawn
- 2002-10-03 AT AT02766997T patent/ATE345775T1/de active
- 2002-10-03 AU AU2002331480A patent/AU2002331480B2/en not_active Expired
- 2002-10-03 DE DE60216305T patent/DE60216305T2/de not_active Expired - Lifetime
-
2004
- 2004-04-01 IL IL161214A patent/IL161214A/en active IP Right Grant
-
2007
- 2007-01-25 CY CY20071100100T patent/CY1105953T1/el unknown
-
2008
- 2008-01-15 IL IL188774A patent/IL188774A0/en unknown
-
2010
- 2010-02-19 JP JP2010034701A patent/JP4926256B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bailly et al. | Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times | |
| Falzone et al. | SnapShot: cancer chemotherapy | |
| ES2964764T3 (es) | Combinación terapéutica que comprende un inhibidor de cdk y oxaliplatino | |
| Chen et al. | Engineered plant-derived nanovesicles facilitate tumor therapy: natural bioactivity plus drug controlled release platform | |
| JP2013503174A5 (enExample) | ||
| Manegold et al. | Gemcitabine in non-small cell lung cancer (NSCLC) | |
| JP2013527232A5 (enExample) | ||
| KR20120004523A (ko) | Ｄｎａ 손상제를 강화시키기 위한 체크포인트 키나제 1 억제제 | |
| Nevins et al. | Nanotechnology approaches for prevention and treatment of chemotherapy‐induced neurotoxicity, neuropathy, and cardiomyopathy in breast and ovarian cancer survivors | |
| JP2012523435A5 (enExample) | ||
| CA2462369A1 (en) | Compositions for delivery of drug combinations | |
| RU2008141763A (ru) | Лечение рака молочной железы, негативного по трем рецепторам | |
| JP2010532364A5 (enExample) | ||
| JP2005508920A5 (enExample) | ||
| NZ599878A (en) | Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents | |
| JP2011520921A5 (enExample) | ||
| CN102772416A (zh) | 包含GSK-3β抑制剂和SBE7-β-CD的药物组合物 | |
| Tang et al. | Combination of baicalein and 10-hydroxy camptothecin exerts remarkable synergetic anti-cancer effects | |
| Karati et al. | A comprehensive review on targeted cancer therapy: new face of treatment approach | |
| JP2007277240A5 (enExample) | ||
| Mühr-Wilkenshoff et al. | A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma | |
| Pierantoni et al. | Pancreatic cancer: progress in cancer therapy | |
| Patwekar et al. | Mechanistic insights on anticancer drugs with specific biological targets and signalling pathways | |
| Iqubal et al. | A technical note on emerging combination approach involved in the onconanotherapeutics | |
| JP2012508240A5 (enExample) |